Table 2.
Nuclear β-Catenin Localization in Human HCC Facilitates ROD
| Nuclear β-catenin accumulation |
|||||
|---|---|---|---|---|---|
| Clinical features | No n (%) | Low n (%) | Medium n (%) | High n (%) | P |
| Vessel invasion | |||||
| Absent | 13 (14) | 32 (36) | 33 (37) | 12 (13) | 0.0018 |
| Present | 3 (7) | 7 (16) | 20 (47) | 13 (30) | |
| Cirrhosis | |||||
| No | 1 (6) | 1 (6) | 10 (63) | 4 (25) | 0.0396 |
| Yes | 15 (13) | 38 (32) | 43 (37) | 21 (18) | |
| Grading | |||||
| G1-2 | 14 (13) | 35 (32) | 45 (41) | 17 (15) | 0.0475 |
| G3 | 2 (9) | 4 (18) | 8 (36) | 8 (36) | |
| Metastasis | |||||
| Absent | 16 (13) | 36 (30) | 49 (41) | 20 (17) | 0.0530 |
| Present | 0 (0) | 3 (25) | 4 (33) | 5 (42) | |
| ROD | |||||
| No | 13 (16) | 27 (34) | 26 (33) | 13 (16) | 0.0142 |
| Yes | 3 (6) | 12 (22) | 27 (50) | 12 (22) | |
G, histological grade; no, low, medium or high, nuclear β-catenin immunoreactivity has exclusively been evaluated in hepatocytes of the HCC. Metastases include diseased lymph nodes as well as distal metastases. P < 0.05 was considered as statistically significant.